U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H27N5O7S.3H2O
Molecular Weight 547.579
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ASPOXICILLIN TRIHYDRATE

SMILES

O.O.O.CNC(=O)C[C@@H](N)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)C3=CC=C(O)C=C3

InChI

InChIKey=TXQFNMPGORBMME-GPIZLFNGSA-N
InChI=1S/C21H27N5O7S.3H2O/c1-21(2)15(20(32)33)26-18(31)14(19(26)34-21)25-17(30)13(9-4-6-10(27)7-5-9)24-16(29)11(22)8-12(28)23-3;;;/h4-7,11,13-15,19,27H,8,22H2,1-3H3,(H,23,28)(H,24,29)(H,25,30)(H,32,33);3*1H2/t11-,13-,14-,15+,19-;;;/m1.../s1

HIDE SMILES / InChI

Description
Sources: DOI: 10.1016/S0065-7743(08)60861-1
Curator's Comment: description was created based on several sources, including: http://www.drugfuture.com/chemdata/ASPOXICILLIN.html http://www.120ty.net/bencandy.php?fid=232&id=36758 http://www.229877.com/article/2012/1209/31983.html

Aspoxicillin is an injectable, amino acid-type penicillin highly active against Gram-positive ad Gram-negative bacteria, including the beta-lactamase producing Bacillus fragilis. It is reportedly effective in the treatment of peritonitis, pneumonia and bronchitis. Adverse reactions are: rash, urticaria, skin itching, vomiting, abdominal pain.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Peritonitis
22
Sources: http://www.229877.com/article/2012/1209/31983.html DOI: 10.1016/S0065-7743(08)60861-1
 Curative
Approved
8583
Doyle

Approved Use

It is reportedly effective in the treatment of peritonitis
Pneumonia
91
Sources: DOI: 10.1016/S0065-7743(08)60861-1 http://www.229877.com/article/2012/1209/31983.html
 Curative
Approved
8583
Doyle

Approved Use

It is used for treatment of pneumonia
Bronchitis
51
Sources: DOI: 10.1016/S0065-7743(08)60861-1 http://www.229877.com/article/2012/1209/31983.html
 Curative
Approved
8583
Doyle

Approved Use

It is used for treatment of chronic and acute bronchitis
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
73.6 μg/g
CLINICAL TRIAL
https://pubmed.ncbi.nlm.nih.gov/3851864/
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ASPOXICILLIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
40.3 μg/g
CLINICAL TRIAL
https://pubmed.ncbi.nlm.nih.gov/3851864/
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ASPOXICILLIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.3 h
CLINICAL TRIAL
https://pubmed.ncbi.nlm.nih.gov/3851864/
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ASPOXICILLIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1.4 h
CLINICAL TRIAL
https://pubmed.ncbi.nlm.nih.gov/3851864/
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ASPOXICILLIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 4 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7706179/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/7706179/
Disc. AE: Serum transaminase increased...
AEs leading to
discontinuation/dose reduction:
Serum transaminase increased (2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7706179/
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
Disc. AE: Eruption, Anorexia...
Other AEs: Fever, Chills...
AEs leading to
discontinuation/dose reduction:
Eruption (2.3%)
Anorexia (0.8%)
Other AEs:
Fever (0.8%)
Chills (0.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
AEs

AEs

AESignificanceDosePopulation
Serum transaminase increased 2%
Disc. AE
4 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 4 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7706179/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/7706179/
Chills 0.8%
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
Fever 0.8%
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
Anorexia 0.8%
Disc. AE
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
Eruption 2.3%
Disc. AE
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3925036/
PubMed

PubMed

TitleDatePubMed
Comparative in vitro activity of 16 antimicrobial agents against Actinobacillus pleuropneumoniae.
2002-01
Antimicrobial susceptibility of Pasteurella multocida isolated from cattle and pigs.
2001-09
Morphological changes and lysis induced by beta-lactams associated with the characteristic profiles of affinities of penicillin-binding proteins in actinobacillus pleuropneumoniae.
2000-06
Aspoxicillin versus piperacillin in severe abdominal infections--a comparative phase III study.
1994-11
Patents

Patents

US4053609 A
2

Sample Use Guides

In Vivo Use Guide
Curator's Comment: For children: 40-80 mg/kg; in severe cases – 60 mg/kg, 2-4 injections per day
1-2 g twice a day, in severe infections – 6-8 g per day
Route of Administration: Intravenous
In Vitro Use Guide
The MIC90 values of aspoxicillin was 0.05 ug/ml for Actinobacillus pleuropneumoniae.
Name Type Language
ASPOXICILLIN HYDRATE
JAN  
Preferred Name English
ASPOXICILLIN TRIHYDRATE
Common Name English
ASPOXICILLIN HYDRATE [JAN]
Common Name English
GLYCINAMIDE, N-METHYL-D-ASPARAGINYL-N-((2S,5R,6R)-2-CARBOXY-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO(3.2.0)HEPT-6-YL)-2-(4-HYDROXYPHENYL)-, HYDRATE (1:3), (2R)-
Common Name English
Code System Code Type Description
PUBCHEM
12905357
Created by admin on Mon Mar 31 21:37:07 GMT 2025 , Edited by admin on Mon Mar 31 21:37:07 GMT 2025
PRIMARY
EPA CompTox
DTXSID80151908
Created by admin on Mon Mar 31 21:37:07 GMT 2025 , Edited by admin on Mon Mar 31 21:37:07 GMT 2025
PRIMARY
CAS
117774-38-6
Created by admin on Mon Mar 31 21:37:07 GMT 2025 , Edited by admin on Mon Mar 31 21:37:07 GMT 2025
PRIMARY
FDA UNII
QL05X0PL6T
Created by admin on Mon Mar 31 21:37:07 GMT 2025 , Edited by admin on Mon Mar 31 21:37:07 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of ASPOXICILLIN
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966